Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder
The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and...
Gespeichert in:
| Veröffentlicht in: | PloS one 2017-05, Vol.12 (5), p.e0177310 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | e0177310 |
| container_title | PloS one |
| container_volume | 12 |
| creator | Ball, Jordan P Springer, Michael J Ni, Yawei Finger-Baker, Isaac Martinez, Juan Hahn, Jessica Suber, John F DiMarco, Ashley V Talton, James D Cobb, Ronald R |
| description | The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac™ norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine. |
| doi_str_mv | 10.1371/journal.pone.0177310 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1900214203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A491954250</galeid><doaj_id>oai_doaj_org_article_1b6db55a547349de9de6fba38eeb7676</doaj_id><sourcerecordid>A491954250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-25145502b0f4ba99b9ace309cb7661c613bf9993578c3553c54b439ba2f9ff3f3</originalsourceid><addsrcrecordid>eNqNku2LFCEcx4couuvqP4gaCIJe7Kbjw6xvguPoYeHgoKe3oo7Ouri6qbN1_31OO3fsQEEoKvr5fZWv36p6DsESoha-3YYheuGW--D1EsC2RRA8qM4hQ82CNgA9PFmfVU9S2gJA0IrSx9VZsyKYQADOK772OQovknB1p5096HhbB1OLWtqDcNrn2ocYDjYOqT4IpazXtQlxNziRdVdbXws_jsnmoe61c9b3dVdE9uFnp-PT6pERLuln03xRffvw_uvVp8X1zcf11eX1QlHW5EVDICYENBIYLAVjkgmlEWBKtpRCRSGShjGGSLtSiBCkCJYYMSkaw4xBBl1UL4-6excSn7xJHDIAGoiLBYVYH4kuiC3fR7sT8ZYHYfmfjRB7LmK2ymkOJe0kIYLgFmHW6dKpkQKttC7vaWnRejfdNsid7pQeTXQz0fmJtxvehwMnGFHagiLwahKI4cegU_7HkyeqLz_BrTehiKmdTYpfYgYZwQ0ZtZZ_oUrr9M6qkg5jy_6s4M2soDBZ_8q9GFLi6y-f_5-9-T5nX5-wGy1c3qTghmyDT3MQH0EVQ0pRm3vnIOBjuO_c4GO4-RTuUvbi1PX7ors0o99Yc_Ti</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1900214203</pqid></control><display><type>article</type><title>Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder</title><source>PLoS (Open access)</source><source>MEDLINE</source><source>Full-Text Journals in Chemistry (Open access)</source><source>PubMed Central</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Ball, Jordan P ; Springer, Michael J ; Ni, Yawei ; Finger-Baker, Isaac ; Martinez, Juan ; Hahn, Jessica ; Suber, John F ; DiMarco, Ashley V ; Talton, James D ; Cobb, Ronald R</creator><contributor>Xing, Zheng</contributor><creatorcontrib>Ball, Jordan P ; Springer, Michael J ; Ni, Yawei ; Finger-Baker, Isaac ; Martinez, Juan ; Hahn, Jessica ; Suber, John F ; DiMarco, Ashley V ; Talton, James D ; Cobb, Ronald R ; Xing, Zheng</creatorcontrib><description>The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac™ norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0177310</identifier><identifier>PMID: 28545100</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Administration, Intranasal ; Adults ; Age ; Aloe - chemistry ; Animal models ; Animals ; Antibodies ; Antibody response ; Antigens ; Attachment ; Bacteria ; Baculovirus ; Balancing ; Biology and life sciences ; Blood cells ; Blood groups ; Buffers ; Caliciviridae Infections - immunology ; Caliciviridae Infections - prevention & control ; Capsid protein ; Carbohydrates ; Cation exchange ; Cell culture ; Cell density ; Chromatography ; Correlation ; Developing countries ; Diarrhea ; Dilution ; Dose-Response Relationship, Drug ; Epidemics ; Female ; Formulations ; Gastroenteritis ; Gels - chemistry ; Gene mapping ; Genotypes ; Guinea Pigs ; Health aspects ; Immune response (humoral) ; Immune system ; Immunity, Mucosal ; Immunization ; Immunogenicity ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulins ; Immunology ; Infections ; Insects ; LDCs ; Lymphocytes B ; Medicine and Health Sciences ; Neutralization Tests ; Norovirus ; Norovirus - immunology ; Norovirus - pathogenicity ; Outbreaks ; Physical Sciences ; Polysaccharides ; Powders - chemistry ; Proteins ; R&D ; Replication ; Research & development ; Research and Analysis Methods ; Risk factors ; Secretions ; Studies ; Vaccines ; Viral Vaccines - administration & dosage ; Viral Vaccines - chemistry ; Viral Vaccines - immunology ; Virus-like particles ; Viruses</subject><ispartof>PloS one, 2017-05, Vol.12 (5), p.e0177310</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>2017 Ball et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Ball et al 2017 Ball et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-25145502b0f4ba99b9ace309cb7661c613bf9993578c3553c54b439ba2f9ff3f3</citedby><cites>FETCH-LOGICAL-c692t-25145502b0f4ba99b9ace309cb7661c613bf9993578c3553c54b439ba2f9ff3f3</cites><orcidid>0000-0002-3506-8123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436670/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436670/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28545100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xing, Zheng</contributor><creatorcontrib>Ball, Jordan P</creatorcontrib><creatorcontrib>Springer, Michael J</creatorcontrib><creatorcontrib>Ni, Yawei</creatorcontrib><creatorcontrib>Finger-Baker, Isaac</creatorcontrib><creatorcontrib>Martinez, Juan</creatorcontrib><creatorcontrib>Hahn, Jessica</creatorcontrib><creatorcontrib>Suber, John F</creatorcontrib><creatorcontrib>DiMarco, Ashley V</creatorcontrib><creatorcontrib>Talton, James D</creatorcontrib><creatorcontrib>Cobb, Ronald R</creatorcontrib><title>Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac™ norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine.</description><subject>Administration, Intranasal</subject><subject>Adults</subject><subject>Age</subject><subject>Aloe - chemistry</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Attachment</subject><subject>Bacteria</subject><subject>Baculovirus</subject><subject>Balancing</subject><subject>Biology and life sciences</subject><subject>Blood cells</subject><subject>Blood groups</subject><subject>Buffers</subject><subject>Caliciviridae Infections - immunology</subject><subject>Caliciviridae Infections - prevention & control</subject><subject>Capsid protein</subject><subject>Carbohydrates</subject><subject>Cation exchange</subject><subject>Cell culture</subject><subject>Cell density</subject><subject>Chromatography</subject><subject>Correlation</subject><subject>Developing countries</subject><subject>Diarrhea</subject><subject>Dilution</subject><subject>Dose-Response Relationship, Drug</subject><subject>Epidemics</subject><subject>Female</subject><subject>Formulations</subject><subject>Gastroenteritis</subject><subject>Gels - chemistry</subject><subject>Gene mapping</subject><subject>Genotypes</subject><subject>Guinea Pigs</subject><subject>Health aspects</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunity, Mucosal</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Infections</subject><subject>Insects</subject><subject>LDCs</subject><subject>Lymphocytes B</subject><subject>Medicine and Health Sciences</subject><subject>Neutralization Tests</subject><subject>Norovirus</subject><subject>Norovirus - immunology</subject><subject>Norovirus - pathogenicity</subject><subject>Outbreaks</subject><subject>Physical Sciences</subject><subject>Polysaccharides</subject><subject>Powders - chemistry</subject><subject>Proteins</subject><subject>R&D</subject><subject>Replication</subject><subject>Research & development</subject><subject>Research and Analysis Methods</subject><subject>Risk factors</subject><subject>Secretions</subject><subject>Studies</subject><subject>Vaccines</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - chemistry</subject><subject>Viral Vaccines - immunology</subject><subject>Virus-like particles</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNku2LFCEcx4couuvqP4gaCIJe7Kbjw6xvguPoYeHgoKe3oo7Ouri6qbN1_31OO3fsQEEoKvr5fZWv36p6DsESoha-3YYheuGW--D1EsC2RRA8qM4hQ82CNgA9PFmfVU9S2gJA0IrSx9VZsyKYQADOK772OQovknB1p5096HhbB1OLWtqDcNrn2ocYDjYOqT4IpazXtQlxNziRdVdbXws_jsnmoe61c9b3dVdE9uFnp-PT6pERLuln03xRffvw_uvVp8X1zcf11eX1QlHW5EVDICYENBIYLAVjkgmlEWBKtpRCRSGShjGGSLtSiBCkCJYYMSkaw4xBBl1UL4-6excSn7xJHDIAGoiLBYVYH4kuiC3fR7sT8ZYHYfmfjRB7LmK2ymkOJe0kIYLgFmHW6dKpkQKttC7vaWnRejfdNsid7pQeTXQz0fmJtxvehwMnGFHagiLwahKI4cegU_7HkyeqLz_BrTehiKmdTYpfYgYZwQ0ZtZZ_oUrr9M6qkg5jy_6s4M2soDBZ_8q9GFLi6y-f_5-9-T5nX5-wGy1c3qTghmyDT3MQH0EVQ0pRm3vnIOBjuO_c4GO4-RTuUvbi1PX7ors0o99Yc_Ti</recordid><startdate>20170518</startdate><enddate>20170518</enddate><creator>Ball, Jordan P</creator><creator>Springer, Michael J</creator><creator>Ni, Yawei</creator><creator>Finger-Baker, Isaac</creator><creator>Martinez, Juan</creator><creator>Hahn, Jessica</creator><creator>Suber, John F</creator><creator>DiMarco, Ashley V</creator><creator>Talton, James D</creator><creator>Cobb, Ronald R</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3506-8123</orcidid></search><sort><creationdate>20170518</creationdate><title>Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder</title><author>Ball, Jordan P ; Springer, Michael J ; Ni, Yawei ; Finger-Baker, Isaac ; Martinez, Juan ; Hahn, Jessica ; Suber, John F ; DiMarco, Ashley V ; Talton, James D ; Cobb, Ronald R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-25145502b0f4ba99b9ace309cb7661c613bf9993578c3553c54b439ba2f9ff3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Intranasal</topic><topic>Adults</topic><topic>Age</topic><topic>Aloe - chemistry</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Attachment</topic><topic>Bacteria</topic><topic>Baculovirus</topic><topic>Balancing</topic><topic>Biology and life sciences</topic><topic>Blood cells</topic><topic>Blood groups</topic><topic>Buffers</topic><topic>Caliciviridae Infections - immunology</topic><topic>Caliciviridae Infections - prevention & control</topic><topic>Capsid protein</topic><topic>Carbohydrates</topic><topic>Cation exchange</topic><topic>Cell culture</topic><topic>Cell density</topic><topic>Chromatography</topic><topic>Correlation</topic><topic>Developing countries</topic><topic>Diarrhea</topic><topic>Dilution</topic><topic>Dose-Response Relationship, Drug</topic><topic>Epidemics</topic><topic>Female</topic><topic>Formulations</topic><topic>Gastroenteritis</topic><topic>Gels - chemistry</topic><topic>Gene mapping</topic><topic>Genotypes</topic><topic>Guinea Pigs</topic><topic>Health aspects</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunity, Mucosal</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Infections</topic><topic>Insects</topic><topic>LDCs</topic><topic>Lymphocytes B</topic><topic>Medicine and Health Sciences</topic><topic>Neutralization Tests</topic><topic>Norovirus</topic><topic>Norovirus - immunology</topic><topic>Norovirus - pathogenicity</topic><topic>Outbreaks</topic><topic>Physical Sciences</topic><topic>Polysaccharides</topic><topic>Powders - chemistry</topic><topic>Proteins</topic><topic>R&D</topic><topic>Replication</topic><topic>Research & development</topic><topic>Research and Analysis Methods</topic><topic>Risk factors</topic><topic>Secretions</topic><topic>Studies</topic><topic>Vaccines</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - chemistry</topic><topic>Viral Vaccines - immunology</topic><topic>Virus-like particles</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ball, Jordan P</creatorcontrib><creatorcontrib>Springer, Michael J</creatorcontrib><creatorcontrib>Ni, Yawei</creatorcontrib><creatorcontrib>Finger-Baker, Isaac</creatorcontrib><creatorcontrib>Martinez, Juan</creatorcontrib><creatorcontrib>Hahn, Jessica</creatorcontrib><creatorcontrib>Suber, John F</creatorcontrib><creatorcontrib>DiMarco, Ashley V</creatorcontrib><creatorcontrib>Talton, James D</creatorcontrib><creatorcontrib>Cobb, Ronald R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ball, Jordan P</au><au>Springer, Michael J</au><au>Ni, Yawei</au><au>Finger-Baker, Isaac</au><au>Martinez, Juan</au><au>Hahn, Jessica</au><au>Suber, John F</au><au>DiMarco, Ashley V</au><au>Talton, James D</au><au>Cobb, Ronald R</au><au>Xing, Zheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-05-18</date><risdate>2017</risdate><volume>12</volume><issue>5</issue><spage>e0177310</spage><pages>e0177310-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac™ norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28545100</pmid><doi>10.1371/journal.pone.0177310</doi><tpages>e0177310</tpages><orcidid>https://orcid.org/0000-0002-3506-8123</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2017-05, Vol.12 (5), p.e0177310 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1900214203 |
| source | PLoS (Open access); MEDLINE; Full-Text Journals in Chemistry (Open access); PubMed Central; Directory of Open Access Journals; EZB Electronic Journals Library |
| subjects | Administration, Intranasal Adults Age Aloe - chemistry Animal models Animals Antibodies Antibody response Antigens Attachment Bacteria Baculovirus Balancing Biology and life sciences Blood cells Blood groups Buffers Caliciviridae Infections - immunology Caliciviridae Infections - prevention & control Capsid protein Carbohydrates Cation exchange Cell culture Cell density Chromatography Correlation Developing countries Diarrhea Dilution Dose-Response Relationship, Drug Epidemics Female Formulations Gastroenteritis Gels - chemistry Gene mapping Genotypes Guinea Pigs Health aspects Immune response (humoral) Immune system Immunity, Mucosal Immunization Immunogenicity Immunoglobulin A Immunoglobulin G Immunoglobulins Immunology Infections Insects LDCs Lymphocytes B Medicine and Health Sciences Neutralization Tests Norovirus Norovirus - immunology Norovirus - pathogenicity Outbreaks Physical Sciences Polysaccharides Powders - chemistry Proteins R&D Replication Research & development Research and Analysis Methods Risk factors Secretions Studies Vaccines Viral Vaccines - administration & dosage Viral Vaccines - chemistry Viral Vaccines - immunology Virus-like particles Viruses |
| title | Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T17%3A10%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intranasal%20delivery%20of%20a%20bivalent%20norovirus%20vaccine%20formulated%20in%20an%20in%20situ%20gelling%20dry%20powder&rft.jtitle=PloS%20one&rft.au=Ball,%20Jordan%20P&rft.date=2017-05-18&rft.volume=12&rft.issue=5&rft.spage=e0177310&rft.pages=e0177310-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0177310&rft_dat=%3Cgale_plos_%3EA491954250%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1900214203&rft_id=info:pmid/28545100&rft_galeid=A491954250&rft_doaj_id=oai_doaj_org_article_1b6db55a547349de9de6fba38eeb7676&rfr_iscdi=true |